Evaluation
*
*

Thinking about the impact of this session on your patients, please offer an estimate of the:

*
%
*
/month
*
1 (Disagree)2345 (Agree)
Describe current treatment options for patients with hepatocellular carcinoma (HCC), including those refractive to first-line anti-VEGF therapy
Recognize toxicities associated with systemic anti-VEGF therapies and other treatment modalities, including how to anticipate their occurrence in patients with HCC
Manage and mitigate anti-VEGF treatment-related adverse events in patients with HCC, including methods for dose adjustments
*
1 (Low)2345 (High)
Al Benson, III, MD, FACP, FASCO
Bridget O'Brien, DNP, APRN, FNP-BC, AOCNP
*
*